Table 2 Comparisons of clinical characteristics among different groups
| Â | Â | Total n = 17 (%) | Adjuvant Group n = 5 (%) | Palliative Group n = 6 (%) | Control Group n = 6 (%) | P value |
|---|---|---|---|---|---|---|
Age (Mean ± SD) | 55.6 ± 8.6 | 53.4 ± 4.7 | 60.0 ± 12.5 | 53.2 ± 5.1 | 0.324 | |
Sex | Â | Â | Â | Â | 0.133 | |
   F | 4 (23.5) | 0 (0) | 1 (16.7) | 3 (50.0) |  | |
   M | 13 (76.5) | 5 (100.0) | 5 (83.3) | 3 (50.0) |  | |
Viral Hepatitis | Â | Â | Â | Â | 0.135 | |
   HBV | 11 (64.7) | 4 (80.0) | 5 (83.3) | 2 (33.3) |  | |
   HCV | 6 (35.3) | 1 (20.0) | 1 (16.7) | 4 (66.7) |  | |
C-P Classification | Â | Â | Â | Â | 0.522 | |
   A | 10 (58.8) | 4 (80.0) | 2 (33.3) | 4 (66.7) |  | |
   B | 4 (23.5) | 1 (20.0) | 2 (33.3) | 1 (16.7) |  | |
   C | 3 (17.6) | 0 (0) | 2 (33.3) | 1 (16.7) |  | |
Pre-OLT BCLC Staging | Â | Â | Â | Â | 0.011 | |
   A | 1 (5.9) | 1 (20.0) | 0 (0) | 0 (0) |  | |
   B | 6 (35.3) | 4 (80.0) | 1 (16.7) | 1 (16.7) |  | |
   C | 7 (41.2) | 0 (0) | 2 (33.3) | 5 (83.3) |  | |
   D | 3 (17.6) | 0 (0) | 3 (50.0) | 0 (0.0) |  | |
Donor Type | Â | Â | Â | Â | 0.624 | |
   CD | 15 (88.2) | 5 (100) | 5 (83.3) | 5 (83.3) |  | |
   LD | 2 (11.8) | 0 (0) | 1 (16.7) | 1 (16.7) |  | |
1 st Relapse Site | Â | Â | Â | Â | 0.052 | |
   Liver | 6 (35.3) | 1 (20.0) | 2 (33.3) | 3 (50.0) |  | |
   Lung | 4 (23.5) | 0 (0) | 2 (33.3) | 2 (33.3) |  | |
   Portal vein | 2 (11.8) | 0 (0) | 2 (33.3) | 0 (0.0) |  | |
   No relapse | 5 (29.4) | 4 (80.0) | 0 (0) | 1 (16.7) |  | |